Guidance for Introgen Therapeutics, Inc. (INGN)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $366.00M – 373.00M | $385.20M | = Maintained | Details |
| 2025 | N/A | N/A | $352.00M – 355.00M | $344.60M | = Maintained | Details |
| Q1 2025 | N/A | N/A | $79.00M – 81.00M | $78.10M | = Maintained | Details |
| 2024 | N/A | N/A | $329.00M – 331.00M | $327.30M | = Maintained | Details |
| 2024 | N/A | N/A | $325.00M – 330.00M | $322.80M | = Maintained | Details |
| Q2 2024 | N/A | N/A | $81.00M – 84.00M | $84.17M | = Maintained | Details |
| Q1 2024 | N/A | N/A | $73.00M – 74.00M | $80.60M | = Maintained | Details |
| 2020 | N/A | N/A | $385.00M – 400.00M | $403.47M | = Maintained | Details |
| 2019 | N/A | N/A | $370.00M – 375.00M | $408.90M |  Lowered |
Details |
| 2019 | N/A | N/A | $405.00M – 415.00M | $433.73M | Lowered |
Details |
| 2019 | N/A | N/A | $430.00M – 440.00M | $436.35M | = Maintained | Details |
| 2019 | N/A | N/A | $430.00M – 440.00M | $429.50M |  Raised |
Details |
| 2018 | N/A | N/A | $345.00M – 355.00M | $349.97M | Raised |
Details |
| 2018 | N/A | N/A | $340.00M – 350.00M | $323.11M | Raised |
Details |
| 2018 | N/A | N/A | $310.00M – 320.00M | $304.32M | Raised |
Details |
| 2018 | N/A | N/A | $298.00M – 308.00M | $302.10M | Raised |
Details |
| 2018 | N/A | N/A | $295.00M – 305.00M | $285.50M | Raised |
Details |
| 2017 | N/A | N/A | $244.00M – 248.00M | $241.76M | Raised |
Details |
| 2017 | N/A | N/A | $233.00M – 239.00M | $234.50M | = Maintained | Details |
| Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| 2015 | N/A | N/A | $145.00M – 149.00M | N/A | Raised |
Details |
| 2015 | N/A | N/A | $133.00M – 137.00M | N/A | = Maintained | Details |
| 2014 | N/A | N/A | $102.00M – 106.00M | $95.80M | Raised |
Details |
| 2014 | N/A | N/A | $92.00M – 96.00M | $91.70M | = Maintained | Details |
